NO20065097L - Flytende veksthormonformulering - Google Patents

Flytende veksthormonformulering

Info

Publication number
NO20065097L
NO20065097L NO20065097A NO20065097A NO20065097L NO 20065097 L NO20065097 L NO 20065097L NO 20065097 A NO20065097 A NO 20065097A NO 20065097 A NO20065097 A NO 20065097A NO 20065097 L NO20065097 L NO 20065097L
Authority
NO
Norway
Prior art keywords
growth hormone
metal salt
liquid growth
hormone formulation
alkaline earth
Prior art date
Application number
NO20065097A
Other languages
English (en)
Other versions
NO337249B1 (no
Inventor
Karine Luet Kleiber
Tudor Arvinte
Original Assignee
Ares Trading Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading Sa filed Critical Ares Trading Sa
Publication of NO20065097L publication Critical patent/NO20065097L/no
Publication of NO337249B1 publication Critical patent/NO337249B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH

Abstract

Foreliggende oppfinnelse gjelder en flytende formulering som omfatter et veksthormon eller en forbindelse som stimulerer frigjøring eller forsterker aktiviteten av endocent hGH, en polyetylenpolypropylenglykol, en citrat/fosfatbuffer, et alkalimetallsalt og et alkalisk jordmetallsalt eller et pseudoalkalisk jordmetallsalt, samt en fremgangsmåte for fremstilling derav.
NO20065097A 2004-04-07 2006-11-06 Flytende veksthormonformulering NO337249B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04101444 2004-04-07
PCT/EP2005/051448 WO2005105148A2 (en) 2004-04-07 2005-03-30 Liquid growth hormone formulation

Publications (2)

Publication Number Publication Date
NO20065097L true NO20065097L (no) 2007-01-02
NO337249B1 NO337249B1 (no) 2016-02-22

Family

ID=34928942

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20065097A NO337249B1 (no) 2004-04-07 2006-11-06 Flytende veksthormonformulering

Country Status (24)

Country Link
US (1) US7662393B2 (no)
EP (1) EP1740213B9 (no)
JP (1) JP4991522B2 (no)
KR (1) KR101120879B1 (no)
CN (1) CN100574801C (no)
AT (1) ATE547121T1 (no)
AU (1) AU2005237775B2 (no)
BR (1) BRPI0508798A (no)
CA (1) CA2559918A1 (no)
CY (1) CY1113834T1 (no)
DK (1) DK1740213T3 (no)
EA (1) EA010626B1 (no)
ES (1) ES2383994T3 (no)
HK (1) HK1098708A1 (no)
HR (1) HRP20120235T1 (no)
IL (1) IL178416A (no)
MX (1) MXPA06011029A (no)
NO (1) NO337249B1 (no)
PL (1) PL1740213T3 (no)
PT (1) PT1740213E (no)
RS (1) RS52310B (no)
SI (1) SI1740213T1 (no)
UA (1) UA89781C2 (no)
WO (1) WO2005105148A2 (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1174457B1 (en) * 1999-12-03 2004-12-22 Toray Industries, Inc. Biaxially stretched polyester film for forming
EP2142207A4 (en) * 2007-04-04 2013-01-16 Theratechnologies Inc PHARMACEUTICAL FORMULATIONS OF GHRH MOLECULES
EP2525833A2 (en) 2010-01-22 2012-11-28 Novo Nordisk Health Care AG Stable growth hormone compounds
CN106139158A (zh) 2010-01-22 2016-11-23 诺沃—诺迪斯克保健股份有限公司 体内功效延长的生长激素
EP2417982A1 (en) * 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
US20140194356A1 (en) 2011-07-25 2014-07-10 Sandoz Ag Aqueous formulation comprising at least a neutral salt and a biopharmaceutical protein
US8871713B2 (en) * 2013-03-01 2014-10-28 Theratechnologies Inc. Formulations of growth hormone releasing factor (GRF) molecules with improved stability
US11045523B2 (en) 2013-04-05 2021-06-29 Novo Nordisk Healthcare Ag Formulation of growth hormone albumin-binder conjugate
EP3431508A4 (en) * 2016-03-14 2019-08-14 JCR Pharmaceuticals Co., Ltd. SERUM ALBUMIN-20-K-GROWTH HORMONE FUSION PROTEIN
US20200237652A1 (en) * 2017-08-08 2020-07-30 Csl Behring Ag Hemopexin formulations
WO2024026224A1 (en) 2022-07-29 2024-02-01 University Of Rochester Methods for improving muscle mass, strength, or function with a combination of testosterone and growth hormone

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3325223A1 (de) * 1983-07-13 1985-01-24 Hoechst Ag, 6230 Frankfurt Gegen denaturierung bestaendige, waessrige proteinloesungen, verfahren zu ihrer herstellung und ihre verwendung
JPS60123426A (ja) * 1983-12-07 1985-07-02 Eisai Co Ltd 経鼻投与用セクレチン製剤
DE3584560D1 (de) * 1984-04-09 1991-12-05 Du Pont Arzneimittelzusammensetzung geeignet zur behandlung oder prophylaxe von herzstoerungen.
PT83095B (en) * 1985-07-30 1987-12-23 Int Minerals & Chem Corp Method for the stabilization of growth promoting hormones using polyoxyethylene-polyoxypropylene copolymers
US5681814A (en) * 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
HUT67319A (en) * 1991-08-30 1995-03-28 Life Medical Sciences Inc Compositions for treating wounds
SE9201073D0 (sv) * 1992-04-03 1992-04-03 Kabi Pharmacia Ab Protein formulation
ATE359824T1 (de) * 1992-07-31 2007-05-15 Genentech Inc Wässrige formulierung enthaltend menschliches wachstumshormon
JPH0892125A (ja) * 1994-09-21 1996-04-09 Nippon Chem Res Kk 水性医薬組成物
AUPN801296A0 (en) * 1996-02-12 1996-03-07 Csl Limited Stabilised growth hormone formulation and method of preparation thereof
US20020077461A1 (en) * 1996-04-24 2002-06-20 Soren Bjorn Pharmaceutical formulation
US6759393B1 (en) * 1999-04-12 2004-07-06 Pfizer Inc. Growth hormone and growth hormone releasing hormone compositions
JP2003504346A (ja) * 1999-07-12 2003-02-04 グランデイス・バイオテツク・ゲー・エム・ベー・ハー 成長ホルモン製剤
EP1309312A2 (en) * 2000-08-07 2003-05-14 Inhale Therapeutic Systems, Inc. Inhaleable spray dried 4-helix bundle protein powders having minimized aggregation
CA2466642C (en) * 2001-11-14 2011-01-18 Guohua Chen Injectable depot composition
AR040526A1 (es) * 2002-07-09 2005-04-13 Grandis Biotech Gmbh Formulaciuones de hgh en alta concentracion que contienen fenol
WO2004082707A2 (en) * 2003-03-18 2004-09-30 Ares Trading Sa Stabilisation of growth hormones in solution

Also Published As

Publication number Publication date
PL1740213T3 (pl) 2012-08-31
RS52310B (en) 2012-12-31
KR20070005628A (ko) 2007-01-10
NO337249B1 (no) 2016-02-22
EP1740213B1 (en) 2012-02-29
WO2005105148A3 (en) 2006-07-20
SI1740213T1 (sl) 2012-04-30
EP1740213B9 (en) 2012-06-13
UA89781C2 (uk) 2010-03-10
BRPI0508798A (pt) 2007-09-04
AU2005237775B2 (en) 2010-03-04
HK1098708A1 (en) 2007-07-27
WO2005105148A2 (en) 2005-11-10
KR101120879B1 (ko) 2012-02-27
WO2005105148A8 (en) 2005-12-08
IL178416A0 (en) 2007-02-11
EA200601874A1 (ru) 2007-02-27
JP4991522B2 (ja) 2012-08-01
ES2383994T3 (es) 2012-06-28
AU2005237775A1 (en) 2005-11-10
EA010626B1 (ru) 2008-10-30
IL178416A (en) 2012-12-31
CN100574801C (zh) 2009-12-30
US20080038292A1 (en) 2008-02-14
PT1740213E (pt) 2012-03-21
MXPA06011029A (es) 2007-01-25
CA2559918A1 (en) 2005-11-10
DK1740213T3 (da) 2012-04-10
US7662393B2 (en) 2010-02-16
JP2007532515A (ja) 2007-11-15
EP1740213A2 (en) 2007-01-10
CN1946427A (zh) 2007-04-11
CY1113834T1 (el) 2016-07-27
ATE547121T1 (de) 2012-03-15
HRP20120235T1 (hr) 2012-04-30

Similar Documents

Publication Publication Date Title
CY1113834T1 (el) Υγρο παρασκευασμα αυξητικης ορμονης
EA015464B9 (ru) Гербицидные составы с улучшенной эффективностью
TW200735773A (en) Insecticidal compositions with improved activity
TW200735897A (en) HFSH aqueous formulation
TR200002812T2 (tr) Efervesan formülasyonları.
ME00414B (me) KRISTALI KOJI SADRŽE N-[2-(DIETILAMINO) ETIL]-5-[(5-FLUOR0-2-0KS0-3H-INDOL-3-ILIDEN)METIL]-2, 4-DIMETIL-lH-PIROL-3-KARBOKSAMID SO JABUČNE KISELINE, PROCESI ZA NJIHOVU PRIMENU I NJIHOVI PREPARATI
WO2008057802A3 (en) Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same
TR200801337T1 (tr) Suda zayıf çözülebilen farmasötik ajanlar ve antimikrobiyal ajanlar içeren kompozisyonlar.
WO2002062844A3 (en) Long lasting growth hormone releasing factor derivatives
BRPI0510527A (pt) método de estabilização de proteìnas
MX2012006831A (es) Formacion de anticuerpos.
CL2004000782A1 (es) Composicion farmaceutica parenteral que comprende (a) piperacilina, (b) tazobactamo, y un acido aminocarboxilico quelante, que ademas puede contener un tampon, como citrato, y opcionalmente un aminoglicosido; procedimientos para su preparacion; y uso
CY1105167T1 (el) Συνθεσεις πepιεχουσες ενα κοσμετολογικα ενepγο οργανικο οξυ και ενα προϊον οσπριου
GEP20084340B (en) Pharmaceutical compositions comprising fentanyl for intranasal delivery
MY146947A (en) Antiparasitic agent for fish and method of controlling proliferation of fish parasites
CY1117174T1 (el) ΧΡΗΣΗ 24-norUDCA ΓΙΑ ΤΗΝ ΑΓΩΓΗ ΧΟΛΟΣΤΑΤΙΚΩΝ ΝΟΣΗΜΑΤΩΝ ΤΟΥ ΗΠΑΤΟΣ
RU2011122629A (ru) Водная композиция, содержащая фолликулостимулирующий гормон
WO2008102349A3 (en) Terbinafine formulation for iontophoresis
EA202091398A1 (ru) Составы вакцинных композиций от вируса денге
TW200744993A (en) Crystalline forms of the di-sodium salt of N-(5-chlorosalicyloyl)-8-aminocaprylic acid
WO2004082707A3 (en) Stabilisation of growth hormones in solution
EP1767090A4 (en) CLATHRATE COMPOUND, METHOD FOR CONTROLLING THE CONCENTRATION OF AQUEOUS SOLUTION IN AN AGROCHEMICAL ACTIVE INGREDIENT, AND AGROCHEMICAL PREPARATION
MY157943A (en) Aqueous suspension concentrates
ZA202204982B (en) Stable formulation of integrin antibody
MX2009011817A (es) Formulaciones de aminoacido n-halogenado que contienen acido alifatico.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees